Prostaglandin E₂ Levels of Aqueous and Vitreous Humor in Ketorolac 0.4% and Nepafenac 0.1% Administered Healthy Rabbits

REFERENCES

• Warner TD, Mitchell JA. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J. 2004;18:790–804.
   PubMed Web of Science ®Google Scholar
• Kim SJ, Flach AJ, Jampol LM. Nonsteroidal anti-inflammatory drugs in ophthalmology. Surv Ophthalmol. 2010;55:108–133.
   PubMed Web of Science ®Google Scholar
• Heier JS, Awh CC, Busbee BG, et al. Vitreous nonsteroidal antiinflammatory drug concentrations and prostaglandin E2 levels in vitrectomy patients treated with ketorolac 0.4%, bromfenac 0.09%, and nepafenac 0.1%. Retina. 2009;29:1310–1313.
   PubMed Web of Science ®Google Scholar
• Rho DS. Treatment of acute pseudophakic cystoid macular edema: diclofenac versus ketorolac. J Cataract Refract Surg. 2003;29:2378–2384.
   PubMed Web of Science ®Google Scholar
• Callanan D, Williams P. Topical nepafenac in the treatment of diabetic macular edema. Clin Ophthalmol. 2008;2:689–692.
   PubMedGoogle Scholar
• Ke TL, Graff G, Spellman JM, et al. Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation. II. In vitro bioactivation and permeation of external ocular barriers. Inflammation. 2000;24:371–384.
   PubMed Web of Science ®Google Scholar
• Gamache DA, Graff G, Brady MT, et al. Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation. I. Assessment of anti-inflammatory efficacy. Inflammation. 2000;24:357–370.
   PubMed Web of Science ®Google Scholar
• Wolf EJ, Braunstein A, Shih C, et al. Incidence of visually significant pseudophakic macular edema after uneventful phacoemulsification in patients treated with nepafenac. J Cataract Refract Surg. 2007;33:1546–1549.
   PubMed Web of Science ®Google Scholar
• Yilmaz T, Cordero-Coma M, Gallagher MJ. Ketorolac therapy for the prevention of acute pseudophakic cystoid macular edema: a systematic review. Eye (Lond)</i>. 2012;26:252–258.
   PubMed Web of Science ®Google Scholar
• Guex-Crosier Y. The pathogenesis and clinical presentation of macular edema in inflammatory diseases. Doc Ophthalmol. 1999;97(3–4):297–309.
   PubMed Web of Science ®Google Scholar
• von Rahden BH, Stein HJ, Pühringer F, et al. Coexpression of cyclooxygenases (COX-1, COX-2) and vascular endothelial growth factors (VEGF-A, VEGF-C) in esophageal adenocarcinoma. Cancer Res. 2005;65:5038–5044.
   PubMed Web of Science ®Google Scholar
• Liu JH. Circadian variations of prostaglandins in the rabbit aqueous humor. J Ocul Pharmacol Ther. 2000;16:49–54.
   PubMed Web of Science ®Google Scholar
• Kapin MA, Yanni JM, Brady MT, et al. Inflammation-mediated retinal edema in the rabbit is inhibited by topical nepafenac. Inflammation. 2003;27:281–291.
   PubMed Web of Science ®Google Scholar
• Yanni SE, Clark ML, Yang R, et al. The effects of nepafenac and amfenac on retinal angiogenesis. Brain Res Bull. 2010;81(2–3):310–319.
   PubMed Web of Science ®Google Scholar
• Lindstrom R, Kim T. Ocular permeation and inhibition of retinal inflammation: an examination of data and expert opinion on the clinical utility of nepafenac. Curr Med Res Opin. 2006;22:397–404.
   PubMed Web of Science ®Google Scholar
• Bucci FA Jr, Waterbury LD. Prostaglandin E2 inhibition of ketorolac 0.45%, bromfenac 0.09%, and nepafenac 0.1% in patients undergoing phacoemulsification. Adv Ther. 2011;28:1089–1095.
   PubMed Web of Science ®Google Scholar
• Bucci FA Jr, Waterbury LD. A randomized comparison of to-aqueous penetration of ketorolac 0.45%, bromfenac 0.09% and nepafenac 0.1% in cataract patients undergoing phacoemulsification. Curr Med Res Opin. 2011;27:2235–2239.
   PubMed Web of Science ®Google Scholar
• Kim SJ, Toma HS, Barnett JM, et al. Ketorolac inhibits choroidal neovascularization by suppression of retinal VEGF. Exp Eye Res. 2010;91:537–543.
   PubMed Web of Science ®Google Scholar
• Toma HS, Barnett JM, Penn JS, et al. Improved assessment of laser-induced choroidal neovascularization. Microvasc Res. 2010;80:295–302.
   PubMed Web of Science ®Google Scholar
• Kim SJ, Toma HS. Inhibition of choroidal neovascularization by intravitreal ketorolac. Arch Ophthalmol. 2010;128:596–600.
   PubMedGoogle Scholar
• Rossetti L, Chaudhuri J, Dickersin K. Medical prophylaxis and treatment of cystoid macular edema after cataract surgery. The results of a meta-analysis. Ophthalmology. 1998;105:397–405.
   PubMed Web of Science ®Google Scholar
• Almeida DR, Johnson D, Hollands H, et al. Effect on prophylactic nonsteroidal antiinflammatory drugs on cystoid macular edema assessed using optical coherence tomography quantification of total macular volume after cataract surgery. J Cataract Refract Surg. 2008;34:64–69.
   PubMed Web of Science ®Google Scholar
• Asano S, Miyake K, Ota I, et al. Reducing angiographic cystoid macular edema and blood-aqueous barrier disruption after small-incision phacoemulsification and foldable intraocular lens implantation. Multicenter prospective randomized comparison of topical diclofenac 0.1% and betamethasone 0.1%. J Cataract Refract Surg. 2008;34:57–63.
   PubMed Web of Science ®Google Scholar
• Almeida DR, Khan Z, Xing L, et al. Prophylactic nepafenac and ketorolac versus placebo in preventing postoperative macular edema after uneventful phacoemulsification. J Cataract Refract Surg. 2012;38:1537–1543.
   PubMed Web of Science ®Google Scholar
• Mathys KC, Cohen KL. Impact of nepafenac 0.1% on macular thickness and postoperative visual acuity after cataract surgery in patients at low risk for cystoid macular oedema. Eye (Lond)</i>. 2010;24:90–96.
   PubMed Web of Science ®Google Scholar
• Kim A, Stark WJ. Are topical NSAIDs needed for routine cataract surgery? Am J Ophthalmol. 2008;146:483–485.
   PubMed Web of Science ®Google Scholar
• Ursell PG, Spalton DJ, Whitcup SM, et al. Cystoid macular edema after phacoemulsification: relationship to blood-aqueous barrier damage and visual acuity. J Cataract Refract Surg. 1999;25:1492–1497.
   PubMed Web of Science ®Google Scholar
• Di Pascuale MA, Whitson JT, Mootha VV. Corneal melting after use of nepafenac in a patient with chronic cystoid macular edema after cataract surgery. Eye & Contact Lens. 2008;34:129–130.
   PubMed Web of Science ®Google Scholar
• Gills JP. Voltaren associated with medication keratitis. J Cataract Refract Surg. 1994;20:110.
   PubMed Web of Science ®Google Scholar
• Guidera AC, Luchs JI, Udell IJ. Keratitis, ulceration, and perforation associated with topical nonsteroidal anti-inflammatory drugs. Ophthalmology. 2001;108:936–944.
   PubMed Web of Science ®Google Scholar